

**From:** [Zimmerman, Joseph](#)  
**To:** [AGO - High Cost Prescription Drugs](#)  
**Subject:** In Accordance with 18 VSA 4637(b)  
**Date:** Wednesday, July 22, 2020 4:18:32 PM

---

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

To whom it may concern:

This notice is being submitted in accordance with 18 VSA § 4637(b) to inform you that Ferring Pharmaceuticals has introduced to market the product ORTIKOS (budesonide) extended release capsules. Ferring launched the product on July 20, 2020 with a WAC of \$1200/unit, which exceeds the threshold set for a specialty drug under the Medicare Part D program. Ferring shall provide additional information as required by 18 VSA § 4637(c) as required.

Regards,

Joe

**Joseph Zimmerman**

Vice President, Chief Compliance & Privacy Officer  
Ferring US

P : +19737961619

M: +18622222140

E: [joseph.zimmerman@ferring.com](mailto:joseph.zimmerman@ferring.com)

Ferring Pharmaceuticals Inc.

100 Interpace Parkway

Parsippany NJ 07054

United States

Follow us on [LinkedIn](#), [Twitter](#)

---

Proprietary or confidential information belonging to Ferring Holding SA or to one of its affiliated companies may be contained in the message.

If you are not the addressee indicated in this message (or responsible for the delivery of the message to such person), please do not copy or deliver this message to anyone.

In such case, please destroy this message and notify the sender by reply e-mail.

Please advise the sender immediately if you or your employer do not consent to e-mail for messages of this kind.

Opinions, conclusions and other information in this message represent the opinion of the sender and do not necessarily represent or reflect the views and opinions of Ferring.

---